FORM PTO-1619A Expires 06/30/99 OMB 0651-0027

12-02-1999 I DOMENIA DAN MANAMANTAN MANAMANTAN DAN DAN DAN

U.S. Department of Commerce **Patent and Trademark Office PATENT** 

MM. 24.99

101212556

Submission	nissioner of Patents and Trademark Type	Conveyance Typ			<u>(103).</u>
X New	.,,,,,	X Assignment		t <del>greo</del> ment	
Resubmission (Non-Recordation) Document ID#		License	Change of	Name	
Reel #	n of PTO Error Frame #  Document Frame #	·	Other U.S. Governme ONLY by U.S. Governmental File	nent Iment Agencies) Secret File	
Conveying F	Party(ies)	Mark if additional	names of conveying		ution Date Day Year
Name (line 1)	Esmon, Charles T., on behalf of an	d as Agent for			1999
Name (line 2) [ Second Party Name (line 1)	Howard Hughes Medical Institute				ution Date Day Year
Name (line 2)					
Receiving Pa	arty	Ma	ark if additional name	es of receiving parties	attached
Name (line 1)	Oklahoma Medical Research	Foundation		is an assi receiving	nt to be recorde ignment and the party is not
Name (line 1)	Oklahoma Medical Research	Foundation		is an assi receiving domiciled States, an	ignment and the party is not in the United appointment
	Oklahoma Medical Research  825 N.E. 13th Street	Foundation		is an assi receiving domiciled States, an of a dom represent (Designat	ignment and the party is not in the United appointment estic ative is attached ion must be a
Name (line 2)		Foundation		is an assi receiving domiciled States, an of a dom represent (Designat	ignment and the party is not in the United appointment estic attive is attached ion must be a document from
Name (line 2) [ Address (line 1) [ Address (line 2) [	825 N.E. 13th Street Oklahoma City	Oklahoma	73	is an assi receiving domiciled States, an of a dom represent (Designat separate of Assignment	ignment and the party is not in the United appointment estic attive is attache ion must be a document from
Name (line 2) [ Address (line 1) [ Address (line 2) [ Address (line 3) [	825 N.E. 13th Street	Oklahoma State/Country	73 or the first Receiving	is an assi receiving domiciled States, an of a dom represent (Designat separate of Assignment)	ignment and the party is not in the United appointment estic attive is attached ion must be a document from
Name (line 2) [ Address (line 1) [ Address (line 2) [ Address (line 3) [	825 N.E. 13th Street  Oklahoma City  City	Oklahoma State/Country		is an assi receiving domiciled States, an of a dom represent (Designat separate of Assignment)	ignment and the party is not in the United appointment estic attive is attached ion must be a document from
Name (line 2) [ Address (line 1) [ Address (line 2) [ Address (line 3) [	825 N.E. 13th Street  Oklahoma City  City	Oklahoma State/Country		is an assi receiving domiciled States, an of a dom represent (Designat separate of Assignment)	ignment and the party is not in the United appointment estic attive is attached ion must be a document from
Name (line 2) [ Address (line 1) [ Address (line 2) [ Address (line 3) [ Domestic Re	825 N.E. 13th Street  Oklahoma City  City	Oklahoma State/Country		is an assi receiving domiciled States, an of a dom represent (Designat separate of Assignment)	ignment and the party is not in the United appointment estic attive is attached ion must be a document from
Name (line 2) [ Address (line 1) [ Address (line 2) [ Address (line 3) [  Domestic Re  Name [  Address (line 1) [	825 N.E. 13th Street  Oklahoma City  City	Oklahoma State/Country		is an assi receiving domiciled States, an of a dom represent (Designat separate of Assignment)	ignment and the party is not in the United appointment estic attive is attached ion must be a document from
Name (line 2) [ Address (line 1) [ Address (line 2) [ Address (line 3) [  Domestic Re  Name [  Address (line 1) [  Address (line 2) [	825 N.E. 13th Street  Oklahoma City  City	Oklahoma State/Country		is an assi receiving domiciled States, an of a dom represent (Designat separate of Assignment)	ignment and the party is not in the United appointment estic attive is attached ion must be a document from

Public burden reporting for this collection of information is estimated to average approximately 30 minutes per Cover Sheet to be recorded, including time for reviewing the document an gathering the data needed to complete the Cover Sheet. Send comments regarding this burden estimate to the U.S. Patent and Trademark Office, Chief Information Officer, Washington, D.C. 20231 and to the Office of Information and Regulatory Affairs, Office of Management and Budget, Paperwork Reduction Project (0651-0027), Washington, D.C. 20503. See OMB Information Collection Budget Package 0651-0027, Patent and Trademark Assignment Practice. DO NOT SEND REQUESTS TO RECORD ASSIGNMENT DOCUMENTS TO THIS ADDRESS.

Mail documents to be recorded with required cover sheet(s) information to: OMRF 152 20487/142/211/242/253 Commissioner of Patents and Trademarks, Box Assignments , Washington, D.C. 20231
PATENT

FORM PTO-1619B Expires 06/30/99 OMB 0651-0027	Page 2	U.S. Department of Commerce Patent and Trademark Office PATENT
Correspondent Name and Address	Area Code and Telephone Number	(404) 873-8794
Name Patrea L. Pabst, Esq.		
Address (line 1) Arnall Golden & Gregor	ry, LLP	
Address (line 2) 2800 One Atlantic Center	er	
Address (line 3) 1201 West Peachtree St	reet	,
Address (line 4) Atlanta, GA 30309-3450	)	
Pages Enter the total number of pa including any attachments.	ges of the attached conveyance docum	ment #15
<b>Application Number(s) or Patent Nur</b>	mber(s) Mark if a	additional numbers attached
Enter either the Patent Application Number or the		, , <del>,</del>
Patent Application Number(s) 09182616	5695993 Patent	Number(s)
09182010	3093993	
09378261	5852171	
If this document is being filed together with a new Pate signed by the first named executing inventor.	nt Application, enter the date the patent application	on was Month Day Year
Patent Cooperation Treaty (PCT)		
Enter PCT application number	PCT PCT	PCT
only if a U.S. Application Number	PCT PCT	PCT
has not been assigned.		
Number of Properties  Enter the total	tal number of properties involved. #	4
Fee Amount Fee Amount	for Properties Listed (37 CFR 3.41): \$	160.00
Method of Payment: Enclo Deposit Account	osed X Deposit Account X	
(Enter for payment by deposit account or if addi		01.0507
		01-2507
	Authorization to charge additional fees:	Yes X No
Statement and Signature		
	lief, the foregoing information is true auriginal document. Charges to deposit a	

Signature

OMRF 152 20487/142/211/242/253

PATENT REEL: 010395 FRAME: 0872

Patrea L. Pabst

Reg. No. 31,284

Name of Person Signing

I, Charles T. Esmon of 5800 North Stonewall, Oklahoma City, Oklahoma 73111, on behalf of and as Agent for the Howard Hughes Medical Institute, 4000 Jones Bridge Road, Chevy Chase, Maryland 20815, in consideration of Ten Dollars and other valuable consideration paid to me by Oklahoma Medical Research Foundation, a corporation of the State of Oklahoma having its principal place of business at 825 N.E. 13th Street, Oklahoma City, Oklahoma 73104, the receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto said Oklahoma Medical Research Foundation, its successors and assigns, the entire interest for the United States of America and its territories and all foreign countries and jurisdictions including all rights of priority under the International Convention for the Protection of Industrial Property in a certain invention or improvement in "CLONING AND REGULATION OF AN ENDOTHELIAL CELL PROTEIN C/ACTIVATED PROTEIN C RECEPTOR" by Kenji Fukudome and Charles T. Esmon, described in (1) U.S. Application Serial No. 08/289,699 filed in the United States Patent and Trademark Office on August 12, 1994, now U.S. Patent No. 5,695,993 granted December 9, 1997; (2) U.S. Application Serial No. 08/878,283 filed in the United States Patent and Trademark Office on June 18, 1997, now U.S. Patent No. 5,852,171 granted December 22, 1998, which claims priority to U.S. Application Serial No. 08/289,699 filed in the United States Patent and Trademark Office on August 12, 1994, now U.S. Patent No. 5,695,993 granted December 9, 1997; (3) U.S. Application Serial No. 09/182,616 filed in the United States Patent and Trademark Office on October 29, 1998, which claims priority to U.S. Application Serial No. 08/878,283 filed in the United States Patent and Trademark Office on June 18, 1997, now U.S. Patent No. 5,852,171 granted December 22, 1998, which claims priority to U.S. Application Serial No. 08/289,699 filed in the United States Patent and Trademark Office on August 12, 1994, now U.S. Patent No. 5,695,993 granted December 9, 1997; and (4) U. S. Serial No. 09/378,261 filed in the United States Patent and Trademark Office on August 20, 1999, which claims priority to U.S. Application Serial No. 09/182, 616 filed in the United States Patent and Trademark Office on October 29, 1998, which claims priority to U.S. Application Serial No. 08/878,283 filed in the United States Patent and Trademark Office on June 18, 1997, now U.S. Patent No. 5,852,171 granted December 22, 1998, which claims priority to U.S. Application Serial No. 08/289,699 filed in the United States Patent and Trademark Office on August 12, 1994, now U.S. Patent No. 5,695,993 granted December 9, 1997, and in all Letters Patent of the United States of America and its territories and all foreign countries and jurisdictions which may or shall be granted on said invention, or any parts thereof, or on said application, or any provisional, divisional, continuation, continuation-in-part, renewals, reissue or other applications based in whole or in part thereon. And I agree, for myself and my executor and administrator, with said corporation and its successors and assigns but at its or their expense or charges, hereafter to execute all applications, amended specifications, deeds or other instruments, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said corporation, with specifications and claims in such form as shall be approved by the counsel of said corporation and to vest and confirm in said corporation, its successors and assigns, the legal title to all such patents.

1

OMRF 152/DIV/DIV(2)/DIV(3) 20487/142/211/242/253 "Cloning and Regulation of an Endothelial Cell Protein C/Activated Protein C. Receptor" By: Kenji Fukudome and Charles T. Esmon

U.S.S.N.: 09/182,616 Filed: August 20, 1999 ASSIGNMENT

And I do hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or applications based thereon to said corporation, its successors and assigns.

WITNESS my hand and seal this 224 day of September, 1999.

Charles T. Esmon, on behalf of and as Agent for Howard Hughes Medical Institute

State of Oklahoma )
County of OKLAHOMA )<sup>SS.</sup>

Then personally appeared the above named Charles T. Esmon and acknowledged the foregoing instrument to be his free act and deed, before me, this <u>JJ+L</u> day of <u>SEATEHBER</u>, 1999.

Notary Public

My Commission expires: OCTOBUR J, 2003

SEAL My co

DENISE A. BREWER
Oklahoma County
Notary Public in and for
State of Oklahoma
My commission expires Oct. 2, 2003.

### APPOINTMENT OF INVESTIGATOR AS AGENT

Appointment by the Howard Hughes Medical Institute (the "Institute") of Dr. Charles T. Esmon, an investigator employed by the Institute, as its agent for the purpose of assigning certain rights to the Oklahoma Medical Research Foundation (the "Foundation").

WHEREAS, the Institute and the Foundation collaborate in the active conduct of medical research pursuant to a Collaboration Agreement between them dated as of July 1, 1988 (the "Collaboration Agreement");

WHEREAS, pursuant to the Collaboration Agreement, the Institute has agreed to assign to the Foundation the Institute's rights with respect to inventions, discoveries, improvements, and other intellectual property, whether patentable or copyrightable (each a "subject property"), conceived or reduced to practice in the course of the research program conducted under the Collaboration Agreement by employees of the Institute;

WHEREAS, research conducted pursuant to the Collaboration Agreement by Dr. Esmon while employed by the Institute at the Foundation has resulted in the invention of a certain subject property entitled "The Structure and Properties of a New Member of the Protein C Pathway and its Application to Inflammatory Disease," with respect to which the Foundation seeks to file a patent application (the "Invention");

WHEREAS, the Institute wishes Dr. Esmon to act as its agent for the purpose of assigning the Institute's rights in the invention to the Foundation; and

NOW, THEREFORE, the Institute hereby appoints Dr. Esmon as its agent for the purpose of assigning the Institute's rights in the Invention to the Foundation in accordance with and subject to the conditions of the Collaboration Agreement.

Executed

\_\_\_, 1994

HOWARD HUGHES MEDICAL INSTITUTE

By: W. Maxwell eowan

Vice President and Chief Scientific Officer

ATTESTED:

y: Joan S. Leonard, Esq.

Associate General Counsel and Assistant Secretary



#### UNITED STATES DEPARTMENT OF COMMERCE Patent and Trademark Office

ASSISTANT SECRETARY AND COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231

DATE: 11/09/94

TO:

N08B

KILPATRICK & CODY PATREA L. PABST, ESQ. 1100 PEACHTREE STREET, SUITE 2800 ATLANTA, GEORGIA 30309

RECEIVED

UNITED STATES PATENT AND TRADEMARK OFFICE NOTICE OF RECORDATION OF ASSIGNMENT DOCUMENT

DEC 0 2 1994

THE ENCLOSED DOCUMENT HAS BEEN RECORDED BY THE ASSIGNMENT BRANCH OF THE U.S. PATENT AND TRADEMARK OFFICE. A COMPLETE MICROFILM COPY IS AVAILABLE AT THE U.S. PATENT AND TRADEMARK OFFICE ON THE REEL AND FRAME NUMBER REFERENCED BELOW.

PLEASE REVIEW ALL INFORMATION CONTAINED ON THIS NOTICE. THE INFORMATION CONTAINED ON THIS RECORDATION NOTICE REFLECTS THE DATA PRESENT IN THE PATENT ASSIGNMENT PROCESSING SYSTEM. IF YOU SHOULD FIND ANY ERRORS OR QUESTIONS CONCERNING THIS NOTICE, YOU MAY CONTACT THE EMPLOYEE WHOSE NAME APPEARS ON THIS NOTICE AT 703-308-9723. PLEASE SEND REQUEST FOR CORRECTION TO: U.S. PATENT AND TRADEMARK OFFICE, ASSIGNMENT BRANCH, NORTH TOWER BUILDING, SUITE 10C35, WASHINGTON, D.C. 20231

ASSIGNOR:

DOC DATE: 09/28/94

FUKUDOME, KENJI

ASSIGNOR:

DOC DATE: 09/28/94

ESMON, CHARLES T.

RECORDATION DATE: 10/17/94 NUMBER OF PAGES 007 REEL/FRAME 7167/0985

DIGEST: ASSIGNMENT OF ASSIGNORS INTEREST

ASSIGNEE:

OKLAHOMA MEDICAL RESEARCH FOUNDATION

825 N.E. 13TH STREET

ē

OKLAHOMA CITY, OKLAHOMA 73104

SERIAL NUMBER 8-289699 FILING DATE 08/12/94 PATENT NUMBER ISSUE DATE 00/00/00

EXAMINER/PARALEGAL ASSIGNMENT BRANCH

ASSIGNMENT/CERTIFICATION SERVICES DIVISION

40.00 581 AID

FORM PTO-1595 (Rev. 6-93) OMB No. 0651-0011 (exp. 1994 PATENT	RM COVER SHEET  U.S. DEPARTMENT OF COMMERCE Patent and Trademark Office		
Tab settings □ □ □	<b>Y Y Y</b>		
To the Honorable Commissioner of Patents and Trademarks: F	Please record the attached original documents or copy thereof.		
1. Name of conveying party(ies):	2. Name and address of receiving party(ies)		
Kenji Fukudome Charles T. Esmon	Name: <u>Oklahoma Medical Research</u> Foundation		
Additional name(s) of conveying party(ies) attached?   Yes  No	Internal Address:		
3. Nature of conveyance:			
☑ Assignment ( ☐ Merger	Street Address: 825 N.E. 13th Street		
☐ Security Agreement ☐ Change of Name			
□ Other	City: Oklahoma City State: OK ZIP: 73104		
Execution Date: September 28, 1994 Soth	Additional name(s) & address(es) attached? ロ Yes 啓 No		
Application number(s) or patent number(s):			
If this document is being filed together with a new application	on, the execution date of the application is:		
A. Patent Application No.(s)	B. Patent No.(s)		
08/289,699			
Additional numbers a	ttached? ☐ Yes ☐KNo		
5. Name and address of party to whom correspondence concerning document should be mailed:	6. Total number of applications and patents involved:		
Name: Patrea L. Pabst, Esq.	7.)Total fee (37 CFR 3.41)\$_40.00		
Internal Address: Kilpatrick & Cody	XI Enclosed		
Suite 2800	Authorized to be charged to deposit account any additional fee or credit overpayment		
Street Address: 1100 Peachtree Street	8. Deposit account number:		
City: Atlanta State: GA ZIP: 30309	(Attach duplicate copy of this page if paying by deposit account)		
	SE THIS SPACE 5 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1		
9. Statement and signature.  To the best of my knowledge and belief, the foregoing infonthe original document.   Output  Description:	mation is true and correct and any attached copy is a true copy of		
Patrea L. Pabst  Name of Person Signing  Total number of pages including	Signature  Gottober 12, 199  Date  Gover sheet, attachments, and document:		

We, Kenji Fukudome of 13125 West Park Place, Oklahoma City, Oklahoma 73142, and Charles T. Esmon of 5800 North Stonewall, Oklahoma City, Oklahoma 73111, in consideration of Five Dollars and other valuable consideration paid to us by Oklahoma Medical Research Foundation, a corporation of Oklahoma having its principal place of business at 825 N.E. 13th Street, Oklahoma City, Oklahoma 73104, the receipt of which is hereby acknowledged, do hereby sell, assign and transfer unto said Oklahoma Medical Research Foundation, its successors and assigns, the entire interest for the United States of America and its territories and all foreign countries and jurisdications, including all rights of priority under the International Convention for the Protection of Industrial Property in a certain invention or improvement in "Cloning and Regulation of an Endothelial Cell Protein C/Activated Protein C Receptor" described in U.S. Serial No. 08/289,699 filed August 12, 1994, in the United States Patent and Trademark Office, and in all Letters Patent of the United States and its territories and all foreign countries and jurisdications which may or shall be granted on said invention, or any parts thereof, or on said application, or any divisional, continuation, continuation-in-part, renewals, reissue or other applications based in whole or in part thereon. And we agree, for ourselves and our executors and administrators, with said corporation and its successors and assigns but at its or their expense or charges, hereafter to execute all applications, amended specifications, deeds or other instruments, and to do all acts necessary or proper to secure the grant of Letters Patent in the United States and in all other countries to said corporation, with specifications and claims in such form as shall be approved by the counsel of said corporation and to vest and confirm in said corporation, its successors and assigns, the legal title to all such patents.

And we do hereby authorize and request the Commissioner of Patents and Trademarks of the United States to issue such Letters Patent as shall be granted upon said application or

5 
U Trans
$\infty$

U.S.S.N. 08/289,699 By: Kenji Fukudome, et al. Filed: August 12, 1994 ASSIGNMENT applications based thereon to said corporation, its successors and assigns. WITNESS my hand and seal this day of \_\_\_\_\_ day of \_\_\_\_\_ 1994. Kenji Fukudome State of Oklahoma ) \ss. County of CKLAHCMA Then personally appeared the above named Kenji Fukudome and acknowledged the foregoing instrument to be his free act and deed, before me, this \_\_\_\_\_ day of \_\_\_\_\_\_, 1994. Notary Public OENSE A. BREWER
Notary Public-State of Oklahoma
OKLAHOMA COUNTY
Av Commission Expires OCT 2. 1995 OKLAHOMA COUNTY

My Commission Expires OCT 2, 1995 WITNESS my hand and seal this \_\_\_\_\_ day of \_\_\_\_\_\_, 1994. For Myself and as Agent of the Howard Hughes Medical Institute State of Oklahoma ) ss. County of CXLAHOMA

DENISE A. BREWER
Notary Public-State of Oklahoma
OKLAHOMA COUNTY
My Commission Expires OCT 2, 1995

Notary Public

Assignment made June 3, 1994 by Charles T. Esmon ("Inventor") to the Howard Hughes Medical Institute, a Delaware not-for-profit corporation (the "Institute").

#### Recitals

WHEREAS, Inventor is an employee of the Institute and, as a condition of his employment, has signed the Agreement appended to the Institute's Statement of Policy on Intellectual Property (the "Intellectual Property Agreement");

WHEREAS, pursuant to the Intellectual Property Agreement, the Inventor has agreed (a) to assign to the Institute all rights he may acquire in any invention, discovery, improvement, or other intellectual property, whether or not patentable or copyrightable, developed directly or indirectly as a result of a program of research financed by Institute funds or by funds under the control of the Institute (each a "subject property") and (b) to execute any agreements that may be desired by the Institute in connection with such assignment;

WHEREAS, Inventor has invented The Structure and Properties of a New Member of the Protein C Pathway and its Application to Inflammatory Disease which is described in an invention disclosure dated June 3, 1994, and which may be the subject of a patent application (the "Invention"), and the Invention is a subject property; and

WHEREAS, Inventor seeks to make a formal assignment of his interest in the Invention to the Institute, and the Institute desires the execution of a formal assignment of all of Inventor's right, title and interest in the Invention.

NOW, THEREFORE, the parties agree as follows:

- 1. Assignment. In consideration of the promises contained in and the acts performed and to be performed pursuant to the Intellectual Property Agreement and of other good and valuable consideration, the receipt of which is hereby acknowledged by Inventor, the Inventor hereby assigns to the Institute the entire right, title, and interest in the Invention, any United States patent applications, all corresponding foreign patent applications, and any and all patents issued therefrom, all divisions and continuations based on any of the foregoing, and all claims contained in the United States and foreign continuations—in—part applications and patents which are directed to the Invention.
- 2. <u>Cooperation</u>. Inventor agrees to execute upon request such further assignments, documents, and other instruments as may be necessary or desirable fully and completely to assign the Inventor's interests in the Invention to the Institute and to assist the Institute in applying for, obtaining, and enforcing

patents, copyrights, or other rights in the United States and in any foreign country with respect to any such Invention.

- 3. <u>Parties</u>. The terms and provisions of this Assignment shall inure to the benefit of the Institute and its successors and assigns and shall be binding on the Inventor and his heirs and successors.
- 4. <u>Warranty</u>. The Inventor warrants and represents that he has not entered into any assignment, contract, or understanding in conflict herewith.

Inventor: hade Ean

STATE OF OKLAHOMA

§ §

COUNTY OF OKLAHOMA

ē

Then personally appeared before me the above-named <u>hasler</u> and acknowledged that he executed the foregoing instrument as his free act and deed this <u>3</u> day of

June 19994

Motary Public

SEAL (print name)

My Commission expires <u>07/17/96</u>

Assignment made June 3 , 1994 by Kenji Fukudome ("Inventor") to the Howard Hughes Medical Institute, a Delaware not-for-profit corporation (the "Institute").

## Recitals

WHEREAS, Inventor is an employee of the Institute and, as a condition of his employment, has signed the Agreement appended to the Institute's Statement of Policy on Intellectual Property (the "Intellectual Property Agreement");

WHEREAS, pursuant to the Intellectual Property Agreement, the Inventor has agreed (a) to assign to the Institute all rights he may acquire in any invention, discovery, improvement, or other intellectual property, whether or not patentable or copyrightable, developed directly or indirectly as a result of a program of research financed by Institute funds or by funds under the control of the Institute (each a "subject property") and (b) to execute any agreements that may be desired by the Institute in connection with such assignment;

WHEREAS, Inventor has invented The Structure and Properties of a New Member of the Protein C Pathway and its Application to Inflammatory Disease, which is described in an invention disclosure dated June 3, 1994, and which may be the subject of a patent application (the "Invention"), and the Invention is a subject property; and

WHEREAS, Inventor seeks to make a formal assignment of his interest in the Invention to the Institute, and the Institute desires the execution of a formal assignment of all of Inventor's right, title and interest in the Invention.

NOW, THEREFORE, the parties agree as follows:

- 1. Assignment. In consideration of the promises contained in and the acts performed and to be performed pursuant to the Intellectual Property Agreement and of other good and valuable consideration, the receipt of which is hereby acknowledged by Inventor, the Inventor hereby assigns to the Institute the entire right, title, and interest in the Invention, any United States patent applications, all corresponding foreign patent applications, and any and all patents issued therefrom, all divisions and continuations based on any of the foregoing, and all claims contained in the United States and foreign continuations—in—part applications and patents which are directed to the Invention.
- 2. <u>Cooperation</u>. Inventor agrees to execute upon request such further assignments, documents, and other instruments as may be necessary or desirable fully and completely to assign the Inventor's interests in the Invention to the Institute and to assist the Institute in applying for, obtaining, and enforcing

patents, copyrights, or other rights in the United States and in any foreign country with respect to any such Invention.

- 3. <u>Parties</u>. The terms and provisions of this Assignment shall inure to the benefit of the Institute and its successors and assigns and shall be binding on the Inventor and his heirs and successors.
- 4. <u>Warranty</u>. The Inventor warrants and represents that he has not entered into any assignment, contract, or understanding in conflict herewith.

Inventor:

STATE OF OKLAHOMA

Ş

COUNTY OF OKLAHOMA

S

Then personally appeared before me the above-named <u>Hearing</u> and acknowledged that he executed the foregoing instrument as his free act and deed this <u>3</u> day of <u>Hearing</u>, 1996.

SEAL

(Mass Leaver(print name)

lake Notary Public

My Commission expires 07 1/7 196

NOT 17 94

. III III IMARK

PATENT REEL: 010395 FRAME: 0883

**RECORDED: 11/24/1999**